A recent study conducted by Zhou et al. investigated the significance of HLA class I molecular differentiation differences (HED) in predicting and prognosticating the outcomes of NSCLC patients who received first-line PD-1 blockade in combination with chemotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.